Monolaurin
Best-in-class: Monolaurin
A monoglyceride of lauric acid, popular in antiviral and antimicrobial protocols.
Monolaurin quick facts
| Suggested dose | As directed, typically 600–3,000 mg daily. |
| How often | Daily |
| Who it's for | Antiviral protocols, in full knowledge of the evidence level. |
In vitro activity is well documented; human clinical evidence is essentially absent, which is the honest summary. Popular in chronic viral protocols on mechanistic reasoning rather than trial data. It is also a widely used food emulsifier, so safety at ordinary doses is well established even though efficacy is not.
How Monolaurin actually works
Glycerol monolaurate, a monoglyceride from lauric acid, disrupts the lipid envelope of enveloped viruses and the membranes of some bacteria. The selectivity comes from the envelope requirement — non-enveloped viruses are unaffected, which is a real limitation rather than a detail.
Where to get Monolaurin
Find Monolaurin on iHerb →What it is, why it recurs, and where this fits — free to read.
The H. pylori Protocol →What it is, why it recurs, and where this fits — free to read.
The evidence for Monolaurin
Graded by what exists behind each claim.
✅ Clinically validated
- No good human trials for the marketed antiviral or antibacterial uses.
📊 Correlative data
- Derived from lauric acid, which is abundant in coconut oil and human breast milk. The antimicrobial interest came from the observation that breast milk lipids inhibit enveloped viruses — again an observation about a food, not about a supplement.
🧪 Theoretical / extrapolated benefits
- Demonstrated in-vitro activity against lipid-enveloped viruses and some bacteria, by disrupting the lipid envelope. Whether ingested monolaurin reaches meaningful systemic concentrations is not established — and it is a food additive precisely because it's digestible.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Monolaurin actually does
Monolaurin is glycerol monolaurate: one twelve-carbon lauric acid chain esterified to one hydroxyl of a glycerol. That is a surfactant. It has a greasy tail and a hydrophilic head, it partitions into lipid bilayers, and above a threshold concentration it destabilizes them. Everything the product is sold for follows from that single physical property, and so does everything wrong with the claim.
Two consequences of a physical mechanism. First, it is not selective: a molecule that disorders the envelope of a virus disorders any lipid membrane it reaches at sufficient concentration, which is why dose and location matter more than target identity. Second, resistance is hard to evolve against it — and that is exactly what was found. Glycerol monolaurate was at least 200-fold more bactericidal than lauric acid against Staphylococcus aureus and Streptococcus pyogenes in broth, and no resistance emerged after a year of passaging bacteria at half the minimum bactericidal concentration Schlievert 2012. A membrane is not a target you can mutate away from.
There is also a signaling effect, and it is the strongest in-vivo result the compound has. Applied vaginally in rhesus macaques, glycerol monolaurate inhibited production of the chemokine MIP-3alpha and protected the animals from simian immunodeficiency virus after repeated mucosal challenge Li 2009. That is not simple lysis — it is suppression of the epithelial signal that recruits the target cells the virus needs.
And here is the fact that decides whether any of it applies to a capsule. Monoacylglycerols are the normal end product of dietary fat digestion. Pancreatic lipase cleaves triglycerides into free fatty acids and 2-monoacylglycerol; enterocytes then re-esterify them back into triglyceride for packaging into chylomicrons. Glycerol monolaurate is a permitted food emulsifier precisely because the body treats it as food. A swallowed dose enters a system built to dismantle and reassemble exactly this class of molecule, which is why an oral route has no obvious path to a systemic antimicrobial concentration.
Cell, rodent, human — and where it stops
In broth. At least 200-fold greater bactericidal activity than lauric acid, with biofilm formation prevented and no resistance after a year of selection Schlievert 2012. Concentrations in that system are set by the experimenter in a fixed volume with no liver, no lipase and no blood.
In monkeys, applied to a surface. Intravaginal glycerol monolaurate, repeated high-dose SIV challenge, protection Li 2009. The route is topical. The drug is in contact with the tissue it is protecting.
In mice, swallowed — and this is the only oral animal data there is. Glycerol monolaurate given as a dietary emulsifier to mice on a low-fat diet induced metabolic syndrome, gut microbiota dysbiosis and systemic low-grade inflammation Jiang 2018.
In humans, for the marketed uses: nothing. No randomized trial of oral monolaurin for herpes simplex, for Epstein-Barr, for candida, for staphylococcal carriage or for anything else it is bought for.
So the obstacle here is not dose or population. It is route. Every positive result is in a dish or on a mucosal surface; the only oral result in an animal is a harm signal Jiang 2018. A capsule is neither of those things, and the step from “kills organisms in contact with it” to “kills organisms inside you after you swallow it” has never been attempted, let alone made.
And the number that would settle it does not exist. No study has ever reported a plasma glycerol monolaurate concentration in a human after an oral dose. Without that, the broth concentrations Schlievert 2012 cannot be compared to anything, in either direction. That gap has stayed open for decades, which is itself information about how hard anyone has tried.
Monolaurin — which form, and does it matter
“Monolaurin” on a label is usually a mixture. Commercial glycerol monolaurate is manufactured by esterification and typically contains 1-monolaurin, 2-monolaurin, dilaurin and trilaurin in some ratio. The studied species is the monoester Schlievert 2012 Li 2009, and the di- and tri- forms are ordinary fats. A product that does not state monoester content has not told you how much of the active it contains.
Lauric acid, coconut oil and monolaurin are three different purchases. Lauric acid is the fatty acid; the studies found the monoester at least 200-fold more active than the acid Schlievert 2012, so a coconut oil product is not a natural version of this. It is the weaker molecule.
Pellets against powder, and why it is not cosmetic. The commonest consumer format is a slow-dissolving pellet. Taken with a fatty meal, any monoacylglycerol is delivered into the exact enzymatic environment designed to process it. If there is a rational formulation question for this compound it is whether anything can be done to avoid lipase and bile, and nobody has published an attempt.
What would have to be true, and how you would know it was not
1. The prediction that cuts against the product, stated so it can be broken. At 600–3,000 mg/day, predict no change in anything systemic: hs-CRP flat, white cell count and differential flat, and no change in the antibody titre of any chronic viral infection. There is no evidence any of it reaches blood intact, and no human pharmacokinetic study exists to suggest otherwise.
2. The reframe for the reaction people report on starting. If glycerol monolaurate acts as a surfactant in the gut lumen, the predicted early effects are changes in stool form and in post-meal fullness within a few days — the same effects any emulsifier produces. That is a more parsimonious explanation for feeling rough in week one than a microbial kill, and it is distinguishable: an emulsifier effect tracks with meals and settles as the gut adapts, while nothing about it depends on which organism you believe you have.
3. A harm prediction with a marker, a direction and a window. The only oral animal study reports dysbiosis and systemic low-grade inflammation on chronic dietary exposure Jiang 2018. If that transfers, the human signature is hs-CRP drifting upward over months, not downward. Draw hs-CRP at baseline, 3 months and 6 months. This is the opposite of what is being bought, it follows from the best available oral evidence, and nobody has looked.
What will fool you here: the in-vitro record. It is real, it is strong, and it is doing all of the persuading. A 200-fold potency advantage in broth Schlievert 2012 is a fact about broth.
What nobody has tested yet
There is no human pharmacokinetics of any kind, and one study would end the argument. A single oral dose, plasma glycerol monolaurate by liquid chromatography-tandem mass spectrometry over eight hours, in ten people. If the answer is “below the limit of quantification”, every systemic claim for this product collapses at once; if it is not, the field has its first real number. It has never been published.
Nobody has tried to protect it from lipase. An enteric or lipase-resistant formulation against a plain one, measuring the same plasma concentration, is the obvious next experiment and there is no sign anyone has attempted it.
The contradiction between the two in-vivo results has never been addressed. Topical application protected macaques from a retrovirus Li 2009; dietary administration harmed mice Jiang 2018. Those are different species, doses and routes, and no study has put them in one design to find out which variable is responsible.
And there is no trial in the condition it is mostly bought for. Recurrent herpes simplex. Outbreak frequency over six months against placebo is a straightforward trial with a countable endpoint, and it does not exist.
Monolaurin — its own safety story, not its category's
Food-additive status is not a safety argument for this dose. Glycerol monolaurate is permitted as an emulsifier at the levels used in food. A supplement serving of 600 to 3,000 mg is a deliberate bolus of the isolated compound, and the two situations share a molecule and nothing else. Anybody citing GRAS status to justify a gram is quoting the wrong exposure.
The specific risk on this page is invisible to the person taking it. Chronic dietary glycerol monolaurate produced gut microbiota dysbiosis, metabolic syndrome and systemic low-grade inflammation in mice Jiang 2018. There is no human counterpart of that study, in either direction, and nothing a user would notice would tell them it was happening.
“No known drug interactions” means nobody has looked. There is no interaction study for this compound with anything. That is an absence of investigation, not a clean record, and the two get written the same way on labels.
No upper limit exists and nothing bounds one. Without a human pharmacokinetic study there is no exposure to compare a dose against; the practical ceiling is gastrointestinal tolerance, which is how most people find their dose and is not a safety assessment.
Who should not take it: anyone with a diagnosed infection using this instead of treatment — the human evidence for the marketed uses is zero, and a treatable infection left to a supplement is the actual harm here. And, on the emulsifier argument above, anyone with inflammatory bowel disease should treat a daily surfactant as a question for their gastroenterologist rather than a supplement decision.
Sources read for this page
- Schlievert PM, Peterson ML. Glycerol monolaurate antibacterial activity in broth and biofilm cultures. PLoS One 2012 · PMID 22808139
- Li Q, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009 · PMID 19262509
- Jiang Z, et al. Antimicrobial Emulsifier-Glycerol Monolaurate Induces Metabolic Syndrome, Gut Microbiota Dysbiosis, and Systemic Low-Grade Inflammation in Low-Fat Diet Fed Mice. Molecular Nutrition & Food Research 2018 · PMID 29131494
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Nothing has been shown to move, and that is the finding. There are no good human trials for the antiviral or antibacterial uses this is bought for, so there is no validated endpoint to copy. If you run it anyway, the only defensible read is the frequency of whatever recurrent thing you are aiming at, counted monthly for three months before you start and three months after.
- How long before it means anything: Six months split evenly around the start date, because a rate needs a denominator on both sides of it. Anything shorter is a story about one winter.
- What will fool you: The in-vitro record, which is real and is doing all of the persuading. Monolaurin disrupts lipid envelopes in a dish; whether swallowing it reaches a concentration that matters in a person has never been established, and it is a permitted food additive precisely because it gets digested. That gap has stayed open for decades, which is itself information. It is not a substitute for treatment of a diagnosed infection.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Monolaurin — safety & side effects
- GI upset and a 'die-off' or Herxheimer-like reaction reported when starting, which usually means starting too high.
- No established significant drug interactions.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. The human evidence base is thin relative to how it is marketed.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Monolaurin in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Monolaurin
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | White cells and their differential — the actual immune measurement |
| Vitamin D (25-Hydroxy) | The deficiency with the most credible immune evidence |
| Zinc, Plasma | Real deficiency impairs immune function; excess doesn't help |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney, since 'detox' is what those two organs do |
The Frequent Illness & Immune Resilience panel covers these in one order — 8 markers, $97.65 with the discount applied.
Check results you already have → · All 103 markers A–Z
Monolaurin — frequently asked questions
What is Monolaurin?
A monoglyceride of lauric acid, popular in antiviral and antimicrobial protocols.
What is the suggested dose of Monolaurin?
As directed, typically 600–3,000 mg daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Monolaurin dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Monolaurin?
Coach Cam sources Monolaurin from vetted, top-rated brands on iHerb — use the buy link on this page.
Monolaurin inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Monolaurin is used for
Monolaurin appears under 2 goals in the goal router.
Related Immune & Detox supplements
Where this goes next
Monolaurin is the acute arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.